Published in Cancer Weekly, December 19th, 2000
"The combination of FeRx's novel MTC drug delivery system with Elan's drug delivery technology, and emerging emphasis in oncology provides an excellent match for accelerating clinical development and realizing the potential of our MTC technology," said Jacqueline Johnson, PhD, FeRx.
FeRx's proprietary Magnetic Targeted Carriers (MTCs) are microparticles, composed of elemental iron and activated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.